Clinical Trials Related to Recurrent Glioblastoma

Related studies linked through entity extraction aliases.

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

Status: NOT_YET_RECRUITING
Phase: PHASE1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Status: RECRUITING
Phase: PHASE1

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Status: NOT_YET_RECRUITING
Phase: PHASE1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Status: RECRUITING
Phase: EARLY_PHASE1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Status: RECRUITING
Phase: PHASE1

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Status: RECRUITING
Phase: PHASE1/PHASE2

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Status: RECRUITING
Phase: PHASE1/PHASE2

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Status: RECRUITING
Phase: PHASE2

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Status: RECRUITING
Phase: PHASE1

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma

Status: RECRUITING
Phase: PHASE1

Phase 2 Clinical Trial of KH617

Status: NOT_YET_RECRUITING
Phase: PHASE2

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

Status: RECRUITING
Phase: EARLY_PHASE1

CUE-102 in Recurrent Glioblastoma

Status: RECRUITING
Phase: PHASE1

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Status: RECRUITING
Phase: NA

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

Status: SUSPENDED
Phase: PHASE2

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Status: RECRUITING
Phase: PHASE1

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Status: RECRUITING
Phase: EARLY_PHASE1

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

Status: RECRUITING
Phase: PHASE2

OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

Status: RECRUITING
Phase: PHASE2

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Status: RECRUITING
Phase: EARLY_PHASE1